Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

GermanyBack to Germany

Clinical trials in Chemnitz – page 10

209 clinical trials in Chemnitz, Germany. Every trial is listed in the EU Clinical Trials Register and updated daily.

GermanyOur site in GermanyKlinischeStudien.de(opens in a new tab)
Chemnitz at a glance
209
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

209 trials in Chemnitz

Open in trial search

Chronic myeloid leukaemia

Not yet recruiting

Efficacy of asciminib in chronic phase chronic myeloid leukemia patients with T315I mutation

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Asciminib Hydrochloride
  • Sponsor:Friedrich-Schiller-Universitaet Jena

Glioblastoma

Not yet recruiting

Phase 3 Randomized Study of Niraparib Tosilate Monohydrate vs. Temozolomide in Newly Diagnosed MGMT Unmethylated Glioblastoma

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Temozolomide
  • Sponsor:Neurotrials LLC

Non-small cell lung cancer

Not yet recruiting

Study of Izalontamab Brengitecan versus Platinum-based Chemotherapy for Patients with EGFR-mutated Non-small Cell Lung Cancer after EGFR Inhibitor Treatment

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Diffuse large B-cell lymphoma+2

Not yet recruiting

Study of Loncastuximab Tesirine and Epcoritamab for Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma, High-grade B-cell Lymphoma, or Follicular Lymphoma Grade 3B

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Epcoritamab
  • Sponsor:Universitaet Muenster

Gastrooesophageal cancer+1

Not yet recruiting

Study on the Safety and Effectiveness of Trastuzumab Deruxtecan with Drug Combination for Patients with HER2+ Resectable Esophagogastric Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Fluorouracil
  • Sponsor:Frankfurter Institut Fuer Klinische Krebsforschung IKF GmbH

Acute myeloid leukaemia

Not yet recruiting

Study on the Safety and Effects of AB8939 and Azacitidine for Patients with Relapsed or Refractory Acute Myeloid Leukemia

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Azacitidine
  • Sponsor:Ab Science

Biliary tract disorder

Not yet recruiting

Study on Durvalumab with Chemotherapy for Patients with Advanced Biliary Tract Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:AstraZeneca AB

Sjogren's syndrome

Not recruiting

Efficacy and Safety Evaluation of Dazodalibep in Patients with Moderate-to-Severe Systemic Sjögren’s Syndrome: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Dazodalibep
  • Sponsor:Horizon Therapeutics Ireland Designated Activity Company

Arteriosclerosis

Not recruiting

Study on the Effects of Pelacarsen on Heart Disease in Patients with Cardiovascular Conditions

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Pelacarsen
  • Sponsor:Novartis Pharma AG

Metabolic dysfunction-associated steatohepatitis+1

Not recruiting

Study on the Effectiveness and Safety of Lanifibranor for Adults with Non-Cirrhotic Non-Alcoholic Steatohepatitis (NASH) and Liver Fibrosis Stages F2/F3

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Lanifibranor
  • Sponsor:Inventiva

Migraine

Not recruiting

Study on the Safety and Effectiveness of MEDI0618 for Reducing Migraine Days in Adults with Episodic Migraine

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:MEDI0618
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Systemic lupus erythematosus

Not recruiting

Study on the Effectiveness and Safety of Deucravacitinib for Patients with Active Systemic Lupus Erythematosus (SLE)

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Deucravacitinib
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Other cities in Germany

The busiest research cities in the country

All 518 cities in Germany

Clinical research in Chemnitz

What the registry says about research in the country

01 Hematologic Oncology

Innovative research focusing on lymphomas and leukemias, including studies evaluating novel therapies for chronic lymphocytic leukemia, diffuse large B-cell lymphoma, and acute myeloid leukemia.

  • Multiple myeloma treatments
  • B-cell lymphoma therapies
  • Leukemia interventions

Several trials are investigating combination therapies and targeted treatments to improve patient outcomes.

02 Solid Tumor Research

Groundbreaking studies in gastric cancer and breast cancer, with particular emphasis on HER2-positive tumors and targeted therapeutic approaches.

  • Colorectal cancer treatments
  • Melanoma therapies
  • Glioblastoma interventions

Focus on personalized medicine approaches and combination treatments for various solid tumors.

03 Autoimmune Conditions

Clinical investigations of treatments for Sjögren's Syndrome and other autoimmune disorders, exploring new therapeutic options for patients.

  • Atopic dermatitis treatments
  • Prurigo nodularis studies
  • Inflammatory conditions

Evaluating novel compounds and biologics for chronic autoimmune conditions.

Back to GermanyAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.